-
1
-
-
77953617933
-
Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model
-
1:CAS:528:DC%2BC3cXntVClurc%3D 19921098 10.1007/s11060-009-0049-4
-
Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, Friedrich RE, Kluwe L, Von Deimling A, Mautner VF, Kurtz A (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98:11-19
-
(2010)
J Neurooncol
, vol.98
, pp. 11-19
-
-
Demestre, M.1
Herzberg, J.2
Holtkamp, N.3
Hagel, C.4
Reuss, D.5
Friedrich, R.E.6
Kluwe, L.7
Von Deimling, A.8
Mautner, V.F.9
Kurtz, A.10
-
2
-
-
84863098290
-
Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: A case report
-
3427039 22747746 10.1186/1752-1947-6-179
-
Kim BK, Choi YS, Gwoo S, Park YH, Yang SI, Kim JH (2012) Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. J Med Case Rep 6:179
-
(2012)
J Med Case Rep
, vol.6
, pp. 179
-
-
Kim, B.K.1
Choi, Y.S.2
Gwoo, S.3
Park, Y.H.4
Yang, S.I.5
Kim, J.H.6
-
3
-
-
33644887733
-
MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1
-
1:STN:280:DC%2BD287ktlemtA%3D%3D 16432718 10.1007/s00234-005-0033-4
-
Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Funsterer C (2006) MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 48:160-165
-
(2006)
Neuroradiology
, vol.48
, pp. 160-165
-
-
Mautner, V.F.1
Hartmann, M.2
Kluwe, L.3
Friedrich, R.E.4
Funsterer, C.5
-
4
-
-
79958745151
-
Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors
-
1:CAS:528:DC%2BC3MXnvVOhtLo%3D 3113907 21695156 10.1371/journal.pone. 0021099
-
Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner VF, Rabkin SD, Demestre M (2011) Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS ONE 6:e21099
-
(2011)
PLoS ONE
, vol.6
, pp. 21099
-
-
Spyra, M.1
Kluwe, L.2
Hagel, C.3
Nguyen, R.4
Panse, J.5
Kurtz, A.6
Mautner, V.F.7
Rabkin, S.D.8
Demestre, M.9
-
5
-
-
65349086151
-
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1
-
1:CAS:528:DC%2BD1MXlsVKhs7w%3D 19410195 10.1016/S1470-2045(09)70033-6
-
Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508-515
-
(2009)
Lancet Oncol
, vol.10
, pp. 508-515
-
-
Brems, H.1
Beert, E.2
De Ravel, T.3
Legius, E.4
-
6
-
-
84870243609
-
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial
-
1:CAS:528:DC%2BC38XhslKktL7E 23099009 10.1016/S1470-2045(12)70414-X
-
Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW (2012) Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 13:1218-1224
-
(2012)
Lancet Oncol
, vol.13
, pp. 1218-1224
-
-
Robertson, K.A.1
Nalepa, G.2
Yang, F.C.3
Bowers, D.C.4
Ho, C.Y.5
Hutchins, G.D.6
Croop, J.M.7
Vik, T.A.8
Denne, S.C.9
Parada, L.F.10
Hingtgen, C.M.11
Walsh, L.E.12
Yu, M.13
Pradhan, K.R.14
Edwards-Brown, M.K.15
Cohen, M.D.16
Fletcher, J.W.17
Travers, J.B.18
Staser, K.W.19
Lee, M.W.20
Sherman, M.R.21
Davis, C.J.22
Miller, L.C.23
Ingram, D.A.24
Clapp, D.W.25
more..
-
7
-
-
2342570393
-
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients
-
1:CAS:528:DC%2BD2cXjs1altLc%3D 15207265 10.1016/j.nbd.2004.01.006
-
Frahm S, Mautner VF, Brems H, Legius E, Debiec-Rychter M, Friedrich RE, Knöfel WT, Peiper M, Kluwe L (2004) Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis 16:85-91
-
(2004)
Neurobiol Dis
, vol.16
, pp. 85-91
-
-
Frahm, S.1
Mautner, V.F.2
Brems, H.3
Legius, E.4
Debiec-Rychter, M.5
Friedrich, R.E.6
Knöfel, W.T.7
Peiper, M.8
Kluwe, L.9
-
8
-
-
33644862170
-
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity
-
1:CAS:528:DC%2BD28XhvVelurg%3D 16357008 10.1093/carcin/bgi273
-
Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A (2006) Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27:664-671
-
(2006)
Carcinogenesis
, vol.27
, pp. 664-671
-
-
Holtkamp, N.1
Okuducu, A.F.2
Mucha, J.3
Afanasieva, A.4
Hartmann, C.5
Atallah, I.6
Estevez-Schwarz, L.7
Mawrin, C.8
Friedrich, R.E.9
Mautner, V.F.10
Von Deimling, A.11
-
9
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
16775235 10.1056/NEJMoa055104
-
Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. NEJM 354:2542-2551
-
(2006)
NEJM
, vol.354
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
Bhalla, K.4
O'Brien, S.5
Wassmann, B.6
Tanaka, C.7
Manley, P.8
Rae, P.9
Mietlowski, W.10
Bochinski, K.11
Hochhaus, A.12
Griffin, J.D.13
Hoelzer, D.14
Albitar, M.15
Dugan, M.16
Cortes, J.17
Alland, L.18
Ottmann, O.G.19
-
10
-
-
75749119275
-
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib
-
1:CAS:528:DC%2BC3cXhtFaltbY%3D 19924121 10.1038/clpt.2009.208
-
Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197-203
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 197-203
-
-
Tanaka, C.1
Yin, O.Q.2
Sethuraman, V.3
Smith, T.4
Wang, X.5
Grouss, K.6
Kantarjian, H.7
Giles, F.8
Ottmann, O.G.9
Galitz, L.10
Schran, H.11
-
11
-
-
77956649599
-
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
-
1:CAS:528:DC%2BC3cXhtFyju7bE 20817538 10.1016/j.bmc.2010.08.026
-
Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N (2010) Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18:6977-6986
-
(2010)
Bioorg Med Chem
, vol.18
, pp. 6977-6986
-
-
Manley, P.W.1
Stiefl, N.2
Cowan-Jacob, S.W.3
Kaufman, S.4
Mestan, J.5
Wartmann, M.6
Wiesmann, M.7
Woodman, R.8
Gallagher, N.9
-
12
-
-
75349094716
-
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
-
1:CAS:528:DC%2BC3cXhs1ynu78%3D 19922818 10.1016/j.bbapap.2009.11.008
-
Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453
-
(2010)
Biochim Biophys Acta
, vol.1804
, pp. 445-453
-
-
Manley, P.W.1
Drueckes, P.2
Fendrich, G.3
Furet, P.4
Liebetanz, J.5
Martiny-Baron, G.6
Mestan, J.7
Trappe, J.8
Wartmann, M.9
Fabbro, D.10
-
13
-
-
0030957310
-
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2
-
1:STN:280:DyaK2szltV2lsQ%3D%3D 9207339 10.1001/jama.1997.03550010065042
-
Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57
-
(1997)
JAMA
, vol.278
, pp. 51-57
-
-
Gutmann, D.H.1
Aylsworth, A.2
Carey, J.C.3
Korf, B.4
Marks, J.5
Pyeritz, R.E.6
Rubenstein, A.7
Viskochil, D.8
-
14
-
-
0032914916
-
Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma
-
1:CAS:528:DyaK1MXht1enuro%3D 10451710 10.1002/(SICI)1098-2264(199903)24: 3<283: AID-GCC15>3.0.CO;2-K
-
Kluwe L, Friedrich R, Mautner VF (1999) Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosom Cancer 24:283-285
-
(1999)
Genes Chromosom Cancer
, vol.24
, pp. 283-285
-
-
Kluwe, L.1
Friedrich, R.2
Mautner, V.F.3
-
15
-
-
0034642298
-
Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two different Schwann cell subpopulations
-
1:CAS:528:DC%2BD3MXjt1ai 11115850 10.1093/hmg/9.20.3055
-
Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, Lenard HG, Lázaro C (2000) Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 9:3055-3064
-
(2000)
Hum Mol Genet
, vol.9
, pp. 3055-3064
-
-
Serra, E.1
Rosenbaum, T.2
Winner, U.3
Aledo, R.4
Ars, E.5
Estivill, X.6
Lenard, H.G.7
Lázaro, C.8
-
16
-
-
0037317634
-
Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer
-
1:STN:280:DC%2BD3s%2FksFKmsA%3D%3D 12554893 10.1136/thorax.58.2.122
-
Hakoda Y, Ito Y, Nagate A, Minemura K, Utsumi K, Aoshima M, Ohyashiki K (2003) Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer. Thorax 58:122-126
-
(2003)
Thorax
, vol.58
, pp. 122-126
-
-
Hakoda, Y.1
Ito, Y.2
Nagate, A.3
Minemura, K.4
Utsumi, K.5
Aoshima, M.6
Ohyashiki, K.7
|